pharmaphorum June 7, 2023
Phil Taylor

In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their environment in “near single-cell resolution.”

The project – dubbed MOSAIC (Multi Omic Spatial Atlas in Cancer) – brings together a string of academic cancer research organisations, as well as artificial intelligence company Owkin, which specialises in machine learning models used to find new biomarkers and therapeutic targets from patient samples and spatial biology company NanoString.

MOSAIC is starting life with $50 million in funding from Owkin, and will use a technique known as ‘spatial omics’, which combines gene sequencing with imaging technologies to analyse RNA and proteins not just for their...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: AI (Artificial Intelligence), Biotechnology, Conferences / Podcast, Pharma / Biotech, Provider, Technology, Trends
Quizzing Intel exec Sandra Rivera about generative AI and more
Utilizing AI may reduce maternal and infant mortality
A New Precedent—A.I. Gets the "American Nobel" Prize in Medicine
AI assistants boost productivity but paradoxically risk human deskilling
Clearpath Revolutionizes Medical Image Sharing with AI-powered Patient Solution

Share This Article